Addison's Disease and Type 1 Diabetes Mellitus by Chantzichristos, Dimitrios
 Addison’s Disease and  
Type 1 Diabetes Mellitus 
 
 
 
Dimitrios Chantzichristos 
 
 
 
 
Department of Internal Medicine and Clinical Nutrition 
Institute of Medicine 
Sahlgrenska Academy, University of Gothenburg 
 
 
 
 
 
 
Gothenburg 2018 
 
  
Cover illustration: Vasilis Johan Chantzichristos, “Johnny, the Gorilla” 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addison’s Disease and Type 1 Diabetes Mellitus 
© Dimitrios Chantzichristos 2018 
dimitrios.chantzichristos@gu.se 
 
ISBN 978-91-629-0497-5  
ISBN 978-91-629-0498-2 (PDF) 
 
Printed in Gothenburg, Sweden 2018 
Printed by BrandFactory 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"ἓν οἶδα, ὅτι οὐδὲν οἶδα" 
“I know one thing; that I know nothing” 
 
Socrates, “Plato’s Apology”, Athens, 399 BC  
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ABSTRACT 
Background: Patients with type 1 diabetes (T1DM) and patients with 
Addison’s disease (AD) need life-long replacement therapy with insulin and 
glucocorticoids (GCs), respectively. Both groups have reduced life-
expectancy. Autoimmune polyendocrine syndrome combining T1DM and AD 
is rare and with very limited outcome data available. Patients with concurrent 
T1DM and AD comprise a treatment challenge due to the counter-balancing 
effects of insulin and GCs on glucose metabolism. In patients with diabetes, 
glycated haemoglobin is an excellent diagnostic and therapeutic biomarker. No 
such biomarker of GC action is available for patients with AD. 
Aims: To study the epidemiology of patients with concurrent T1DM and AD. 
More specifically, to investigate the incidence and mortality in patients with 
T1DM and AD, and elucidate early indicators for AD development in this 
population. To discover putative biomarkers of GC action. 
Methods: Population-based, real-world data were derived from six linked 
Swedish National Registries, including the National Diabetes Register. 
Depending on the research question, cases were matched to five control 
subjects: we determined AD incidence (T1DM vs general population), and 
early indicators and mortality (T1DM+AD vs T1DM). The main statistical 
methods used were: Cox regression analysis, analysis of covariance, estimated 
group proportions, and Kaplan-Meier survival curves. The biomarker study 
was a randomised, crossover study in patients with AD, where patients were 
studied during states of near-physiological GC exposure and GC withdrawal. 
Gene expression from peripheral blood mononuclear cells and circulating 
microRNAs and metabolites were integrated into a network analysis. 
Results: The incidence of AD among patients with T1DM was 193 (95% CI: 
152–245) per million patient-years. The risk of developing AD among patients 
with T1DM was 10.8 (95% CI: 7.1–16.5) times higher than in the general 
population. Prodromal signs for the development of AD in patients with T1DM 
were treatment for thyroid disease, infections requiring hospital admission, 
 multiple diabetic complications (retinopathy in particular), and rescue therapy 
for hypoglycaemia. Patients with concurrent T1DM and AD had 4.3 (95% CI: 
2.6–7.0) times increased risk for death than patients with T1DM alone and died 
most frequently from diabetic complications. The biomarker study succeeded 
in generating two completely different states of GC exposure. Integration of 
gene expression data, miRNA and metabolomic data delivered a network 
model with modules of putative biomarkers of GC action. 
Conclusions: The higher risk of AD among patients with T1DM and the higher 
mortality in patients with concurrent T1DM and AD indicate the need of an 
improved strategy for patient management. Finally, the experimental study 
identified novel, potential biomarkers of GC action for further validation. 
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Både personer med typ 1 diabetes mellitus (T1DM) och personer 
med Addisons sjukdom har ökad mortalitet. Båda sjukdomarna är autoimmuna 
och det är känt att förekomsten av en autoimmun sjukdom ökar risken för 
ytterligare en sådan. Att ha både T1DM & Addisons sjukdom är inte väl 
studerat, huvudsakligen på grund av att det är ovanligt. Denna kombination är 
svårbehandlad eftersom hormonerna involverade i sjukdomarna, insulin och 
kortisol, har motverkande effekter på glukosmetabolism. Insulin ersättning kan 
justeras med hjälp av en excellent biomarkör (HbA1c), men ingen sådan 
biomarkör finns för kortisol. 
Mål: Att studera epidemiologi hos personer med T1DM & Addisons sjukdom: 
incidens, mortalitet, samt prediktorer för Addisons sjukdom. Att upptäcka 
potentiella biomarkörer för glukokortikoidernas (GC) effekt. 
Metoder: Population-baserade epidemiologiska studier i personer med T1DM 
& Addisons sjukdom samt matchade kontroller, där data från sex nationella 
register (inkl. Nationella Diabetes Registret) har kombinerats. Cox 
regressionsanalys, analys av kovarians, grupp proportioner, och Kaplan-Meier 
överlevnadskurvor användes. En randomiserad cross-over singel-blind studie i 
personer med Addisons sjukdom under ett tillstånd med nästan fysiologisk 
cirkadisk substitution med GC och ett efter uppehåll med GC, användes för att 
leta efter biomarkören för GC effekt. Resultat av genexpression, microRNA 
och metaboliter i blodet sammanställdes med hjälp av nätverk analys. 
Resultat: Incidens av Addisons sjukdom bland personer med T1DM var 193 
per million person-år (95% CI: 152–245). Personer med T1DM hade en 10.8 
gånger (95% CI: 7.1–16.5) ökad risk av att drabbas av Addisons sjukdom 
jämfört med bakgrundspopulationen. De tidiga tecknen av Addisons sjukdom 
var: behandling mot tyreoidea sjukdom, inneliggande behandling för 
infektioner, multipla diabeteskomplikationer, diabetes retinopati, och akut 
behandling mot hypoglykemi. Personer med T1DM & Addisons sjukdom hade 
4.3 gånger (95% CI: 2.6–7.0) ökad mortalitet jämfört med personer med 
T1DM. Den huvudsakliga dödsorsakeken var diabeteskomplikationer. Baserad 
på mätningar av serum och urin GC:er, biomarkör studien lyckades generera 
två olika tillstånd av GC substitution. Sammanställningen av genexpression, 
microRNA samt metabolit data med nätverk analys indikerade att modellen 
var relevant för att finna markörer för GC effekt. 
Konklusion: Den högre risken att utveckla Addisons sjukdom bland personer 
med T1DM samt den högre mortaliteten i T1DM & Addison sjukdom gruppen, 
betonar vikten av att upptäcka och optimalt behandla Addisons sjukdom hos 
personer med T1DM. Den experimentella studien har potential för upptäckter 
av framtida biomarkörer för GC effekt. 
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1 INTRODUCTION 
 
 
 
 
 
 
 
 
 
1.1 GLUCOCORTICOIDS 
 
Cortisol is the main endogenous GC in humans. Endogenous GC secretion 
from the adrenal glands is under tight dynamic control by the hypothalamic-
pituitary-adrenal axis and is regulated in a circadian (24-h cyclical), pulsatile 
ultradian rhythm (with the amplitude of peaks decreasing during the course of 
the day) and larger pulses in the case of acute stress [1-4]. There is considerable 
evidence in animal models indicating that pulsatile circulating GC levels, via 
transient GC receptor activation, lead to transcriptional pulsing at a genetic 
level [5,6]. 
GCs act via the ubiquitously expressed GC receptor, belonging to the nuclear 
receptor superfamily. The tissue-specific responsiveness to GCs is regulated 
by the pre-receptor metabolism of GCs and the interaction of the GC receptor 
with either tissue-specific transcription factors (which regulate transcription of 
several thousand genes) or non-genomic factors [7-9]. As a result of this 
complexity, circulating levels of cortisol only loosely relate to tissue activity 
of cortisol and this is why serum cortisol has limited value as a biomarker for 
GC action [10,11]. Additionally, there is poor correlation between symptoms 
and serum cortisol levels [12]. 
GCs have a key role in the metabolic, vascular and immunological response to 
stress, and their effects are largely permissive, modulating responses to many 
other stimuli [13]. The metabolic effects of GCs are to promote lipolysis, 
proteolysis and gluconeogenesis. GCs stimulate the deposition of glycogen, 
increase hepatic glucose output, inhibit glucose uptake and utilisation in 
peripheral tissues, and lead to insulin resistance and increased plasma glucose 
levels [14,15]. The metabolic effects of GCs are more pronounced in the 
This thesis studies, systematically and for the first time, the rare 
combination of two metabolic diseases, Addison’s disease (AD) and type 
1 diabetes mellitus (T1DM). Previously, knowledge on the risk of 
developing AD in patients with T1DM and the prognosis of patients 
having both diseases was limited. 
Advances in the care of patients with T1DM are remarkable and 
accelerating in contrast with those for AD. An important role in this 
progress is due to glycated haemoglobin (HbA1c), an excellent biomarker 
that reflects biochemical control and long-term prognosis. This thesis also 
includes an experimental study aimed at identifying putative biomarker(s) 
of glucocorticoid (GC) action. 
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evening than in the morning; elevated evening GC levels have been associated 
with glucose intolerance, abdominal obesity and coronary arteriosclerosis [16-
18]. At the same time, the effects of GCs are highly diverse and there is wide 
inter-individual variation in sensitivity to them [19]. The detailed mechanistic 
pathways by which GCs act remain poorly defined. 
GCs are essential for survival. Extreme excess (Cushing’s syndrome) or 
deficiency (AD) in humans causes striking clinical abnormalities and increased 
mortality [20,21]. More subtle changes in the action of GCs are thought to be 
important in the aetiology of many common diseases such as obesity, 
hypertension and type 2 diabetes mellitus [22]. 
The first synthesis of exogenous GC (11-deoxycortisone) took place in 1937 
[23]. Another synthetic cortisone (compound E or Kendall’s compound) was 
first given to a patient with AD in 1948 [24]. Synthetic GCs have long been 
amongst the most commonly prescribed drugs as they have a central 
therapeutic role in lung disorders, rheumatic diseases, haematological 
malignancies and transplanted patients [25,26]. 
Metabolic side effects of synthetic GCs are common. Patients receiving oral 
GCs have an increased use of diabetic and antihypertensive drugs, increased 
risk of having osteoporotic fractures or cardiovascular events, and excess 
cardiovascular mortality [25,27-30]. The reasons behind these side effects are 
both the non-physiological dose and time-exposure profile [31,32]. A more 
individualised approach based on a biological response marker should improve 
outcome in all patients treated with synthetic GCs. 
 
1.2 ADDISON’S DISEASE 
 
Pathogenesis 
 
In AD or primary adrenal insufficiency, the adrenal cortex has impaired 
production and secretion of GCs (cortisol), mineralocorticoids (aldosterone) 
and adrenal androgens [33]. In developed countries, autoimmune AD 
(predominantly with positive 21-hydroxylase autoantibodies) accounts for 
about 85% of cases [34]. Up to 60% of patients with autoimmune AD have an 
additional autoimmune condition, most frequently thyroid disease (50%) or 
T1DM (12%), which constitutes autoimmune polyendocrine syndrome type 2 
(APS2) [35-37]. 
Autoimmune AD is often characterized by an insidious onset leading to overt 
disease after a varying period of time [38]. In the natural history model of 
autoimmune AD, genetic susceptibility (predominantly specific HLA 
haplotypes) is underlying, which is followed by unknown triggering factors 
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leading to progressive destruction of the adrenal cortex. Elevated plasma renin 
activity is an initial sign followed by the appearance of 21-hydroxylase 
autoantibodies and decreased peak cortisol levels (following a synthetic 
adrenocorticotropic hormone [ACTH] stimulation test); finally, serum ACTH 
is increased and basal cortisol decreased before progression to overt clinical 
disease, in which ACTH is greatly increased and both peak stimulated and 
basal cortisol are greatly decreased [39]. 
 
Epidemiology 
 
The prevalence of AD in different European populations varies between 93 
and 221 per million and has an estimated incidence of 4.4–6.2 per million per 
year. In common with several other autoimmune disorders, prevalence and 
incidence have been rising (Table 1) [35,36,40-44]. Women are more 
frequently affected than men and age at diagnosis peaks between 30 and 50 
years of age [35,40-42]. 
 
Table 1. Incidence and prevalence of AD in European countries. 
 
 
Reference 
 
 
Location 
No. of AD 
cases and 
study 
population size 
AD incidence 
per million 
patient-years 
Prevalence of 
AD per 
million* 
Kong & Jeffcoate 
(1994) [40] 
Nottingham, 
UK 
66 of 600,000 5.6 110 
Willis & Vince 
(1997) [41] 
Coventry, 
UK 
30 of 323,852 – 93 
Laureti et al.  
(1999) [43] 
Umbria, 
Italy 
95 of 811,887 – 117 (95% CI: 
95–143) 
Lovas & Husebye 
(2002) [35] 
Western 
Norway 
128 of 916,000 6.2 140 
Erichsen et al. 
(2009) [36]† 
Norway 664 of 
4,603,263 
4.4 144 
Bjornsdottir et al. 
(2013) [43] 
Sweden 1305 AD cases 6.0 131 
Olafsson & 
Sigurjonsdottir 
(2016) [44] 
Iceland 53 of 239,724 – 221 
*Corresponding 95% CI presented when available. 
†The prevalence of both AD and T1DM (49 among 426 patients with AD) was 20 per million 
patients. 
AD is an inevitably fatal disease in the absence of treatment [45]. Even when 
AD is diagnosed and treated, it is associated with increased risk of premature 
death, mainly due to cardiovascular diseases, cancer, infections, sudden death 
and adrenal crisis [21,36,46]. 
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Diagnosis 
 
The clinical presentation of AD depends on the pace and extent of the loss of 
adrenal function. Diagnosis is delayed because of non-specific symptoms and 
signs. A cross-sectional study found that 20% of the patients suffered for more 
than 5 years before being diagnosed and two-thirds of all patients with AD 
presented to medical professionals three or more times with symptoms of 
adrenal failure before a correct diagnosis was made [47]. Patients affected with 
autoimmune AD display a wide spectrum of clinical presentations and severity, 
often displaying a prolonged, insidious onset [48]. AD may also present with 
an adrenal crisis, which often occurs in the context of a stressful event (such 
as infection or trauma) or in the case of bilateral adrenal infarction, 
haemorrhage or pituitary apoplexy. 
As symptoms of AD are non-specific, a high level of clinical suspicion is 
required to make a correct diagnosis. Common features of AD include weight 
loss, anorexia, nausea, vomiting, lethargy, hypoglycaemia, hyperpigmentation 
of skin and mucosal surfaces, and fatigue (in up to 95% of patients) [38]. In 
addition, postural hypotension, muscle cramps, abdominal discomfort and salt 
craving can arise due to mineralocorticoid insufficiency. In women, loss of 
axillary and pubic hair can arise due to lack of androgens. 
Apart from signs and symptoms, altered drug use is reported before the 
diagnosis of autoimmune AD with increased prescription of gastrointestinal, 
anti-anaemic, thyroid and lipid-modifying drugs as well as systemic 
corticosteroids and antibiotics [43]. Finally, low serum sodium, high serum 
potassium and elevated serum thyroid-stimulating hormone (TSH) may be 
detected before the diagnosis of AD [49]. 
An updated algorithm for the initial investigation of adrenal insufficiency has 
been recently published [50]. The first steps in the diagnostic process comprise 
random cortisol measurements, plasma renin and ACTH measurements, and a 
250-µg synthetic ACTH stimulation test. 
 
Therapy 
 
The goals of GC replacement therapy in patients with AD is to abolish 
symptoms of GC deficiency, prevent adrenal crisis and, at the same time, not 
induce long-term side effects such as osteoporosis, obesity, hypertension and 
type 2 diabetes [29,30,51]. 
Currently, first-line therapy is hydrocortisone (15–25 mg/day) or cortisone 
acetate (25–37.5 mg/day) taken in divided doses twice or three times daily. A 
longer-acting GC, prednisolone (3–5 mg daily), can be used as a once or twice 
daily regimen in patients with poor compliance using multiple daily dose 
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regimens [52]. Most patients with AD also need mineralocorticoid 
replacement, usually fludrocortisone (50–200 µg) once daily. The dose of 
fludrocortisone should be actively adjusted according to measurements of 
plasma renin, serum sodium and potassium, and blood pressure. Replacement 
of adrenal androgens in females has not shown consistent benefit [53]. 
New developments in the therapy of patients with AD include a dual-release 
hydrocortisone preparation (Plenadren®) and continuous subcutaneous 
hydrocortisone infusion (CSHI) using an insulin pump. These therapies have 
shown some advantages in patients with both diabetes and AD compared with 
conventional treatment: significant improvement in glycaemic control with 
dual-release hydrocortisone and more stable night-time glucose levels with 
CSHI [54,55]. 
It is essential to monitor for signs of under- and over-replacement with steroids 
during the follow-up of patients with AD. However, there is no reliable 
biomarker for this during GC replacement. 
 
Adrenal Crisis 
 
Patients with AD are at risk of developing adrenal crisis, a life-threatening 
condition if not rapidly treated with parenteral GCs and saline infusion. In a 
prospective study in patients with primary and secondary adrenal 
insufficiency, the incidence of adrenal crisis was 8.3 per 100 patient-years and 
adrenal crisis-associated mortality was approximately 6% [56]. Patients with 
AD are therefore taught to increase GC dose in the event of infection or other 
physical and mental stressful events in order to prevent a crisis. Continuous 
patient education plays a key role in self-management of AD and potential 
adrenal crisis [57]. In addition, a “steroid card” and medical alert patient 
identification tag are necessary to warn healthcare providers in the case of 
unconsciousness. 
 
1.3 TYPE 1 DIABETES MELLITUS 
 
Pathogenesis 
 
T1DM results from destruction of pancreatic insulin-producing beta cells in 
the islets of Langerhans [58]. As in autoimmune AD, underlying genetic 
susceptibility is probably triggered by environmental agents, which leads to 
overt T1DM after a latent period. A number of different autoantigens have 
been described within beta cells but it is unclear which are involved in the 
initiation of the injury and which are secondary to injury. Autoimmune 
markers include islet-cell autoantibodies and autoantibodies to glutamic acid 
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decarboxylase (GAD), insulin, tyrosine phosphatases IA-2 and IA-2b, and 
ZnT8. 
 
Epidemiology 
 
T1DM is one of the most common chronic diseases of childhood and its 
incidence and prevalence are increasing globally together with many other 
autoimmune diseases [59]. An estimated 30.3 million people of all ages had 
diabetes in 2015 in the USA, equivalent to 9.4% of the total population [60]. 
In Sweden, 44,466 adults and 7,203 children had T1DM in 2015 [61], which 
means that T1DM is approximately 40 times more common than AD. 
Despite the considerable advances in diabetes care, T1DM is still associated 
with premature death [62]. A nationwide Swedish study showed a more than 
2-fold higher risk of death (mainly from cardiovascular diseases and diabetes-
related causes) in patients with on-target glycaemic control and an 8-fold 
higher risk of death in patients with poor glycaemic control compared with the 
general population [63]. In T1DM, nephropathy is a serious comorbidity 
increasing the risk of premature death and the most common diabetic 
complications are microvascular, especially in patients with long-standing 
diabetes [63,64]. A longitudinal US study within a single county explored 
patterns of cause-specific mortality in patients with T1DM [65]. Within the 
first 10 years after diagnosis, the leading cause of death was acute diabetic 
complications (74%) while, during the next 10 years, deaths were attributed to 
acute diabetic complications (15%), cardiovascular (22%), renal (20%) or 
infectious (18%) causes. After 20 years, chronic diabetic complications 
(cardiovascular, renal or infectious) accounted for more than 70% of all deaths, 
with cardiovascular disease as the leading cause of death (40%). 
 
Diagnosis 
 
T1DM usually presents with polyuria, polydipsia, weight loss and diabetic 
ketoacidosis (an acute, major, life-threatening complication). Diagnosis is 
based on the detection of abnormalities in glucose metabolism, including 
elevated fasting plasma glucose, elevated plasma glucose after an oral glucose 
tolerance test, and elevated HbA1c. 
 
Therapy 
 
Patients with T1DM are treated with insulin replacement. Description of the 
different insulin regimens, glycaemic control targets, self-management aspects 
and diabetes education is outside the purpose of this thesis. Nevertheless, it is 
worth mentioning some of the advances in T1DM care which have led to more 
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individualised management. These include patient education programmes, 
telecare intervention, routine assessment of comorbidities including their 
primary prevention, new insulin analogues, and continuous glucose 
monitoring. 
Finally, HbA1c (a measure of glycosylation of haemoglobin) is an excellent 
diagnostic and therapeutic biomarker for patients with T1DM. By measuring 
HbA1c, which is a risk marker for future complications [63], physicians are 
able to get an overall picture of average blood glucose levels over a period of 
up to 12 weeks and tailor treatment accordingly. 
 
1.4 TYPE 1 DIABETES & ADDISON’S DISEASE  
 
Autoimmune Polyendocrine Syndrome Type 2 
 
A patient with one autoimmune disorder is at increased risk of developing 
another autoimmune disease and the frequency of additional autoimmune 
diseases in T1DM shows an age-dependent increase [66]. Up to 60% of 
patients with autoimmune AD have an additional autoimmune condition (e.g. 
thyroid disease, T1DM) constituting APS2 [35-37]. Patients with autoimmune 
thyroid disease have an at least 10-times higher risk of developing other 
autoimmune diseases, e.g. pernicious anaemia, systemic lupus erythematosus, 
AD, coeliac disease [67]. 
 
Incidence and Prevalence 
 
Having both T1DM and AD is rare, which may explain the paucity of outcome 
data in this patient group. Previously published data on the prevalence of 
concurrent T1DM and AD were the result of subanalyses in AD or T1DM 
populations. Between 10.7% and 12% of patients with AD also had T1DM 
[36,68]. The estimated prevalence of concurrent AD and T1DM in Western 
Norway was 20 per million [35] (Table 1). In a US population, 0.3% of patients 
with T1DM were found to have concomitant AD [66]. The risk for T1DM 
patients developing AD has not been determined. In addition, it is unknown 
whether women are more frequently affected than men by both T1DM and AD, 
and whether age at diagnosis of concurrent T1DM and AD peaks between 30 
and 50 years of age as with AD alone. 
 
Insulin vs Cortisol 
 
Having both T1DM and AD is a complicated condition due to the counter-
balancing effects of insulin and cortisol on glucose metabolism. The 
management of both diagnoses during an infection or other stressful events is 
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challenging in order to prevent adrenal crisis and manage hypoglycaemia or 
ketoacidosis. Because of these counter-balancing effects on glucose 
metabolism, patients with T1DM present with reduced insulin requirement 
when they develop severe GC deficiency due to AD [69]. In addition, a study 
of ten patients with both T1DM and AD showed different basal and meal-
related insulin requirements compared with patients having only T1DM [70]. 
Apart from altered insulin requirements, data on prodromal signs and early 
indicators are missing in patients with T1DM that develop AD. 
 
Mortality 
 
With respect to prognosis, previous studies have shown an increased risk of 
potentially life-threatening adrenal crises among patients with both T1DM and 
AD versus patients with AD alone or the general population [56,71,72]. 
Another study has shown that patients with AD who also had diabetes had an 
increased risk of death compared to patients with AD alone [21]. Nevertheless, 
there is no previous national study on the mortality of patients with the 
combination of T1DM and AD. 
 
Other Knowledge Gaps 
 
At present, there is no consensus whether to perform regular screening for AD 
among patients with T1DM as the magnitude of risk is poorly known [73-77]. 
Finally, the complete lack of a biomarker in order to tailor GC replacement and 
balance this with insulin treatment (which is tailored by monitoring HbA1c) is 
profound. 
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2 AIMS 
The hypotheses that generated the studies of this thesis were: 
• Autoimmune AD is more common among patients with T1DM than in the 
general population; 
 
• Patients with T1DM that develop AD may have specific prodromal signs 
that can help in predicting AD; 
 
• Patients with T1DM, after they develop AD, have an additional increased 
risk of death; 
 
• There are circulating biomarkers that reflect the biological action of GCs. 
Consequently, the overall aim of this thesis was to study the epidemiology of 
the combination of T1DM and AD. 
The specific aims were: 
• To study the incidence and the relative risk of developing AD in patients 
with or without T1DM (Paper I). 
 
• To study whether there are signs that denote the development of AD in 
patients with both T1DM and AD before they are diagnosed with AD 
(early indicators) (Paper II). 
 
• To study overall mortality in patients with T1DM and AD (Paper III). 
 
• To study putative biomarkers of GC action (Paper IV). 
 
Addison’s Disease and Type 1 Diabetes Mellitus 
10 
3 PATIENTS AND METHODS 
3.1 EPIDEMIOLOGIC STUDIES 
 
Study Design and Registries 
 
With respect to the epidemiology of the combination of T1DM and AD, we 
conducted three nationwide, matched, observational cohort studies that merged 
data from six different Swedish National Registries (interlinked by a unique 
personal identification code) held by the Swedish National Board of Health 
and Welfare (Figure 1): 
- National Diabetes Register (NDR): coverage >97%, data since 1998 [78]; 
- Swedish Inpatient Register (SNIR): complete coverage, data since 1987 
[79,80]; 
- Cancer Register: complete coverage, data since 1958; 
- Cause of Death Register: complete coverage, data since 1961; 
- Longitudinal Integration Database for Health Insurance and Labor Market 
Studies (LISA; information on education level, income, civil status and 
county): complete coverage, data since 1990 [81]; 
- Prescription Drug Register: complete coverage, data since July 2005 [82]. 
 
Figure 1. Overlap between the registries included in the epidemiological studies. 
 
  
SNIR 
+ other 
registries
NDR
Pat 
with 
ADPat with 
T1DM
Dimitrios Chantzichristos 
11 
All studies were approved by the Regional Ethical Review Board in 
Gothenburg, Sweden (diary numbers 563-12 and 776-14). All research 
complied with the Declaration of Helsinki. 
 
Study Subjects 
 
Subjects (and their comorbidities) were identified using the codes of the 
International Classification of Diseases, Ninth Revision (ICD-9) for years 
1987–1996 and of ICD-10 for years 1997–2015. In the SNIR, the codes used 
to identify patients with AD were ICD-9 code 255.4 and ICD-10 codes E27.1 
and/or E27.2. These search criteria for AD have previously shown high validity 
[21]. Patients with endogenous Cushing's syndrome and/or any disorders of the 
pituitary gland were excluded. For the identification of T1DM in the NDR, we 
used the diagnosis attributed to the patients by the physicians who reported 
them to the register. Details on all ICD-9 and ICD-10 codes used in the studies 
are presented in a supplementary table at the end of this thesis. Codes from 
ICD-7 were used for cancer diagnosis in the Swedish Cancer Register. 
 
Procedures 
 
We conducted three different studies. Table 2 shows the different study 
designs, study periods, groups of cases vs control subjects, the included 
registries, and the primary (AD or overall mortality) and secondary outcomes 
studied in each study. All patients with an AD diagnosis preceding the T1DM 
diagnosis were excluded in all studies. All patients deceased before the end of 
the observation period were excluded from the incidence and early indicators 
studies. Baseline (time point of inclusion in the study) for all studies was 
defined as the date of first registration of cases in the NDR. 
 
Statistical Methods 
 
At baseline, cases were compared with control subjects by descriptive 
statistics. For continuous variables with normal distribution, we performed 
two-sided independent samples t-test where p-value <0.05 was considered to 
be statistically significant. The difference between group proportions for 
binary variables was estimated by the difference in proportions along with the 
corresponding 95% confidence interval (CI). Table 2 shows the statistical 
methods and matching criteria used in each study. 
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Table 2. Overview of the methodology in papers I-III. 
 
 Paper I  
Incidence 
Paper II 
Early indicators 
Paper III  
Mortality 
Study design Cohort, 
longitudinal 
Cohort,  
3 periods 
Cohort,  
longitudinal 
Study period 1998-2013 1998-2015 1996-2012 
Cases 
- Diagnosis 
 
- No. 
 
T1DM 
 
36,514 
 
T1DM who  
developed AD 
66 
 
T1DM who  
developed AD 
148 
Control subjects 
- Diagnosis 
- No. 
 
No T1DM 
182,570 
 
T1DM (no AD) 
330 
 
T1DM (no AD) 
739 
Matching  
criteria 
(5:1) age, sex, 
calendar year at 
inclusion in 
study, and 
county 
(5:1) age, sex, duration 
of T1DM, and calendar 
year at inclusion in 
study 
(5:1) sex, year of birth, 
time from diagnosis of 
T1DM to AD diagnosis 
for cases or T1DM 
duration until inclusion 
for controls, and 
calendar year of T1DM 
and AD diagnosis for 
cases or year of 
registration in the NDR 
for controls 
Outcomes studied 
- primary 
- secondary 
 
AD 
Relative risk of 
AD  
 
AD 
Clinical characteristics, 
drug prescriptions 
 
Overall death 
Cause-specific death 
Registries  
included 
NDR 
SNIR 
LISA 
NDR 
SNIR 
LISA 
Prescribed Drug 
Register 
Cancer Register 
Cause of Death Register 
NDR 
SNIR 
Cancer Register 
Cause of Death 
Register 
Statistics Incidence rate, 
Cox regression, 
Kaplan-Meier 
survival curves 
Analysis of covariance 
(ANCOVA), 
estimated group 
proportions, 
paired t-test 
Standardised mean 
difference (SMD), 
Cox regression,  
Kaplan-Meier survival 
curves 
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Methodological Considerations 
 
The strengths of all the studies were the reliability of the registries included 
and the diagnosis codes studied as well as the selected study procedures, 
including matching. More specifically, all registries have a high national 
coverage and are continuously validated. NDR provides detailed clinical data. 
Both the search criteria for AD in the SNIR and the reported main causes of 
death have been previously shown to have high validity [21,83]. Population-
based national real-world data from the six different registries led to a 
panoramic approach and matching minimised the problem of confounding. By 
using control subjects also registered in the NDR, we reduced the problem of 
detection bias, as patients in this register have a similar frequency of clinical 
assessments. 
Most studies are a compromise, where a hypothesis is studied in an available 
subgroup of a population and with restricted access to data due to different 
reasons. In this respect, our studies also had some methodological limitations. 
One of them was that there were no detailed clinical data for all matched 
control subjects without T1DM as they were not registered in the NDR. 
In the incidence study, the hypothesis was that autoimmune AD is more 
common in patients with T1DM. Due to the lack of data on whether AD was 
autoimmune or not, we assumed that around 85% of the cases studied (as 
published previously in developed countries) actually had autoimmune AD. 
In the early indicators study, a limitation was the limited access to drug 
prescription data, as no data were available for gastrointestinal, anti-anaemic 
and obstructive airway disease drugs for comparison with previous 
observations in patients with autoimmune AD. Moreover, we assessed the date 
of the first registration of the AD diagnosis as the time of the overt AD, when 
it is known that there is variation between the time of actual overt disease onset 
and its diagnosis. 
In the mortality study, we studied the additional mortality in patients with 
T1DM after they were diagnosed with AD; however, we also included patients 
during data collection who were registered with both diseases for first time 
simultaneously. There were relatively few such patients (28 out of 148) and, 
taking in account the natural history of the two diseases, it is possible that the 
majority of them actually had T1DM first and then AD. 
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3.2 EXPERIMENTAL STUDY 
 
Study Design 
 
This was a single-centre, single-blind, randomised, two-period crossover, 
treatment clinical trial under the acronym BIOCORT (NCT02152553). The 
study was approved by the Ethics Review Board of the University of 
Gothenburg, Sweden (diary number 374-13) and written informed consent was 
obtained from all patients before participation. 
 
Study Subjects and Treatment 
 
Men or women with verified AD receiving stable and near-physiological GC 
doses and having no other comorbidities were eligible for the study. 
Hydrocortisone intravenous infusion (1 mg hydrocortisone per 50 ml saline 
0.9%) was adjusted in accordance with previous observations in healthy males 
[3,84] and interventions in both sexes [85,86]. The aim was to achieve a near-
physiological circadian GC exposure with early morning increase in serum 
cortisol that would peak at 7 AM and trough concentrations at midnight (Figure 
2A). Saline 0.9% infusion alone was administered to prevent adrenal crisis in 
the GC withdrawal period. 
 
Interventions 
 
Subjects were randomised before the first intervention to receive either 
intravenous hydrocortisone infusion in 0.9% saline or saline 0.9% infusion 
alone in a single-blind manner at least 2 weeks apart (Figure 2A). The day 
before each intervention, subjects were told not to take their mineralocorticoids 
and to take their usual dose of hydrocortisone. All subjects were admitted after 
an overnight fast and were discharged at 12 AM the day after. During each 
intervention, subjects received standard meals at fixed times and remained 
under minimal stress. Their consumption of coffee or tea was recorded to 
ensure consumption of the same amount and at same times during both 
interventions. 
During each intervention, blood pressure, body temperature and body weight 
were measured. Serum and plasma were collected immediately before the start 
of intervention, at midnight and in the morning (of the second intervention 
day). Overnight urine was also collected. 
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Figure 2. Flow chart of the clinical and analytical part of the biomarker study. (A) Subjects with 
AD were studied twice over 26 h during physiological GC exposure (HC intervention) and GC 
withdrawal (saline intervention) at least 2 weeks apart. Serum and plasma samples were 
collected at midnight (15 h after start) and the next morning (22 h after start). (B) 
Transcriptomics were analysed from morning PBMC samples, whereas miRomics and 
metabolomics were analysed from both midnight and morning blood samples. (C) Stepwise 
integration of the ‘omic data into a network model. 
 
 
 
Analyses (Including Bioinformatics) 
 
The primary endpoint was defined as a network integrating changes in gene 
expression in PBMCs, miRNAs in plasma, and metabolites in serum between 
a state of near-physiological GC exposure (hydrocortisone intervention) and 
GC withdrawal (saline intervention) (Figure 2B). 
The analyses performed in the study were: 
- Plasma cortisol and cortisone analysed using liquid chromatography-mass 
spectrometry (LC-MS), 
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- Urinary free GCs analysed using gas chromatography-mass spectrometry 
(GC-MS), 
- Microarray gene expression analysis in peripheral blood mononuclear cells 
(PBMCs), 
- MicroRNA (miRNA) analysis in plasma, 
- Metabolic profiling of serum using both GC-MS and LC-MS. 
The bioinformatics comprised data analysis of differential gene expression, 
Gene Ontology (to define biological pathways), gene expression regulated by 
miRNA, Causal Network Analysis (to assess regulatory relationships in the 
‘omic data), network model construction and comparison (Figure 2C), and 
Similarity Network Fusion (to define similar groups of patients based on their 
combined ‘omic data). 
 
Statistical Methods 
 
For normally distributed quantitative variables, we performed paired samples 
t-test. For non-normally distributed quantitative variables, Wilcoxon rank test 
was performed. All statistical tests were two-sided and a p-value <0.05 was 
considered to be statistically significant. Statistical analyses were performed 
using SPSS program version 24 software for Mac. 
Unsupervised analysis of transcriptomic and metabolomic data to assess how 
GC exposure grouped the study subjects was performed using Orthogonal 
Projections to Latent Structures Discriminant Analysis (OPLS-DA) using the 
MixOmics plugin [87] for R. This is a statistical modelling tool that is robust 
to collinearity between the variables and provides insights into separation 
between experimental groups. 
 
Methodological Considerations 
 
In order to better understand the mechanistic pathways of GCs and to identify 
potential biomarkers of GC action in humans, a clinical study was found to be 
most appropriate. Most cell lines cannot survive without the presence of GCs 
and cannot be studied in a GC withdrawal state. Cell culture models using 
continuous GC treatment throughout the time course of the experiment are not 
representative of the physiology of GC exposure in vivo. Moreover, most 
animal models have different GCs compared with humans and their impact on 
circadian rhythm is also different. AD is a rare disorder but a unique 
experimental model due to the absence of adrenal GC production. A study 
using oral pharmacological GC exposure in AD patients or in patients with 
endogenous overt Cushing’s syndrome may add complexity to the model as 
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there are secondary effects of high GC exposure, such as activation of the 
mineralocorticoid receptor, impairment in glucose metabolism and increase in 
blood pressure. 
The main strengths of this biomarker discovery study are the use of a human 
GC “knock-out” model (subjects with AD), the study design itself 
(randomisation, blinding, crossover), and the network analysis integrating data 
from three different functional levels (transcriptome, miRNA and 
metabolome). Moreover, interventions including meals and consumption of 
caffeinated drinks were standardised, co-interventions were avoided, and 
subjects remained under minimal stress. 
On the other hand, no power calculation was done because of the complexity 
and the “pilot” nature of the study. Power calculations are rather difficult in 
the context of ‘omic analysis as there may be variable effect sizes over many 
different ‘omic elements. Nevertheless, integration of multiple ‘omic layers 
allows reduction of background noise and allows us to increase confidence in 
the findings. The study design did not allow us to analyse any dose-response 
relationship or individual responsiveness (pharmacogenomics). Moreover, the 
gene expression analysis was performed in a single, important target tissue 
(PBMCs) for GCs and it is therefore possible that other results might be 
obtained if another tissue was studied. However, the measurement of miRNA 
and metabolites from peripheral blood (plasma and serum, respectively) at the 
same time, probably reflects the global effects of GCs. 
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4 RESULTS 
4.1 EPIDEMIOLOGIC STUDIES 
 
Incidence and Relative Risk of AD among Patients with T1DM 
 
Between 1998 and 2013, 66 patients were diagnosed with AD among 36,514 
patients with T1DM and 32 were diagnosed with AD among 182,570 matched 
control subjects without T1DM (general population). Baseline (first 
registration in the NDR for cases) demographics and clinical characteristics for 
the four different groups are presented in Table 3. The difference in mean age 
when AD was diagnosed between patients with T1DM or without T1DM was 
6.3 years (95% CI: 0.4–12.2; p=0.036). Time to AD diagnosis in patients with 
or without T1DM is shown in Figure 3. 
 
Table 3. Baseline (first registration in the NDR for cases) demographics and clinical 
characteristics among patients with or without T1DM and their subgroups with or without AD. 
Results are presented as n (%) for categorical variables and mean (SD) for continuous 
variables. 
 
 T1DM 
(n=36,448) 
T1DM+AD 
(n=66) 
Controls 
(n=182,538) 
Controls+AD 
(n=32) 
Age at T1DM 
   diagnosis (y) 
15.3 (7.7) 13.6 (7.6) – – 
Age at AD 
   diagnosis (y) 
35.2 (14.6) 36.4 (13.0)* 35.2 (14.6) 42.7 (15.2)* 
Male 19,957 (54.8%) 39 (59.1%) 99,966 (54.8%) 14 (43.8%) 
HbA1c (mmol/mol) 66 (16) 68 (15) – – 
HbA1c (%) 8.2 (1.5) 8.4 (1.4) – – 
*The difference between these groups was 6.3 years (95% CI: 0.4–12.2; p=0.036) (t-test). 
 
The incidence of AD among patients with T1DM was 193 (95% CI: 152–245) 
per million patient-years compared with 18 (95% CI: 13–26) per million 
patient-years among matched control subjects without T1DM. The adjusted 
relative risk increase (hazard ratio, adjusted for age and sex) of developing AD 
in patients with T1DM was 10.8 (95% CI: 7.1–16.5) times compared with 
control subjects without T1DM. 
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Figure 3. Time to AD diagnosis in patients with or without T1DM. 
 
 
 
Early Indicators of AD in Patients with T1DM 
 
Prior to baseline (first registration in the NDR) 
The 66 cases with T1DM and AD from the incidence study were matched to 
330 control subjects with only T1DM. Prior to baseline, prescription of thyroid 
and/or antithyroid drugs was higher in cases than in control subjects (9.1% vs 
1.8%, Figure 4). There was no difference in adjusted mean HbA1c nor in the 
frequency of studied comorbidities between the groups. 
Prior to AD diagnosis 
Cases had the same adjusted mean HbA1c as their matched control subjects and 
five variables showed a higher frequency (statistically significant) in cases 
compared with control subjects: 
- Infections requiring hospital admission (16.7% vs 2.1%), 
- Multiple diabetic complications (13.6% vs 4.8%), 
- Diabetic retinopathy (12.1% vs 2.1%), 
- Prescription of thyroid and/or antithyroid drugs (28.8% vs 7.0%), 
- Prescription of glucagon (18.2% vs 6.4%). 
The 66 cases with T1DM who developed AD were then followed for up to 2 
years after the AD diagnosis. Mean HbA1c was at the same level before and 
after AD diagnosis. The frequency of diabetic complications, autoimmune 
diseases and other comorbidities also remained at the same level. Adrenal 
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crisis was recorded in two patients within 2 years after AD diagnosis, while 
none were observed before AD diagnosis. A trend for higher prescription of 
antihypertensive drugs was observed in T1DM and AD patients after AD 
diagnosis compared with the period before diagnosis (47.0% vs 30.3%; 
difference 16.7% [95% CI: –4.2% to 37.5%]). Drug prescription data were 
available after AD diagnosis in up to 56 of 66 cases with T1DM and AD. 
Among the 66 cases, 78.8% were treated with hydrocortisone, 4.5% with 
prednisolone and 3.0% with cortisone acetate. Prescription data for 
fludrocortisone (mineralocorticoid) were available in 55 of the 66 cases, 
among which 57.6% were treated with fludrocortisone and 25.8% were not 
treated. 
 
Figure 4. Frequencies of prescription of thyroid/antithyroid drugs between patients with T1DM 
and AD and T1DM alone prior to baseline (inclusion to the study) and prior to AD diagnosis 
(within 2 years). The statistical significant difference in frequencies (corresponding 95% CIs) 
between the two groups and at both time points are presented. 
 
 
 
Overall Mortality in Patients with T1DM and AD 
 
In the NDR and SNIR, we identified 148 patients (77 men, 71 women) with 
T1DM who then developed AD or were registered with both diagnoses (28 out 
of 148) at the same time between 1996 and 2012. These cases were matched 
1:5 to 739 control subjects (384 men, 355 women) with T1DM based on sex, 
year of birth, time from diagnosis of T1DM to AD diagnosis for cases or 
T1DM duration until inclusion for control subjects, and calendar year of 
T1DM and AD diagnosis for cases or year of registration in the NDR for 
control subjects. At baseline, mean±SD HbA1c was 64±14 mmol/mol or 
8±1.3% in cases and 63±15 mmol/mol or 7.9±1.4% in control subjects. The 
proportion of diabetic retinopathy and multiple diabetic complications were 
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clearly higher in cases than in controls (Table 4). Medical history of infections 
requiring hospital admission was markedly increased in the T1DM and AD 
group compared with the T1DM controls (SMD=46.35). 
 
Table 4. Baseline (first registration in the NDR) clinical data in cases with T1DM and AD, and 
their matched control subjects with T1DM. Data presented as n (%). SMD is a measure of size 
effect, with imbalance between the groups defined as an absolute value >20%. 
 
 T1DM+AD  
(n=148) 
Controls with T1DM 
(n=739) 
 
SMD (%) 
Diabetic nephropathy 8 (5.4%) 15 (2.0%) –17.91 
Diabetic retinopathy 31 (21.0%) 52 (7.0%) –40.93 
Diabetic neuropathy 11 (7.4%) 19 (2.6%) –22.44 
Diabetic angiopathy 8 (5.4%) 11 (1.5%) –21.60 
Multiple diabetic complications 21 (14.0%) 33 (4.5%) –33.91 
History of hypertension 9 (6.1%) 75 (10%) 14.94 
History of coronary heart disease 
including acute myocardial infarction 11 (7.4%) 36 (4.9%) –10.67 
History of congestive heart failure 2 (1.4%) 10 (1.4%) 0.02 
History of stroke 3 (2.0%) 11 (1.5%) –4.10 
History of infections requiring hospital 
admission 46 (31%) 92 (12%) –46.35 
History of cancer 2 (1.4%) 25 (3.4%) 13.39 
 
The observed number of deaths was 29 in the 148 cases (20%) and 35 in the 
739 controls (4.7%). The adjusted relative risk increase (hazard ratio adjusted 
for years at baseline, years at T1DM diagnosis, duration between them and 
sex) in overall mortality of the T1DM and AD group was 4.3 (95% CI: 2.6–
7.0) times compared with matched T1DM controls. The cumulative overall 
mortality in cases vs control subjects is shown in Figure 5. 
 
Figure 5. Cumulative overall mortality in patients with T1DM and AD vs control subjects with 
T1DM. 
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Cause-specific Mortality in Patients with T1DM and AD 
 
There were differences in the main causes of death between cases with T1DM 
and AD and matched control subjects with T1DM (Figure 6). The most 
common main cause of death was due to T1DM complications in both groups, 
whereas deaths from unknown cause and infections were more frequent among 
patients with T1DM and AD. Death from cancer (as main cause of death) was 
more frequent among control subjects with T1DM. 
 
Figure 6. Main causes of death in patients with T1DM and AD vs control subjects with T1DM. 
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4.2 EXPERIMENTAL STUDY 
 
Baseline Characteristics 
 
Eleven subjects with AD with a median age of 50 (range, 25–57) years and a 
median disease duration of 23.5 (range, 1–33) years were included in the study. 
Ten (4 women, 3 of them post-menopausal) completed all aspects of the study. 
The median daily dose of hydrocortisone prior to the study was 30 (range, 20–
30) mg and nine subjects received fludrocortisone at a median daily dose of 
0.1 (range, 0.1–0.2) mg. 
 
Serum and Urinary Glucocorticoids 
 
There was no difference between the two interventions in serum cortisol or 
cortisone collected at baseline, while both were markedly higher in the 
morning of the second day during GC exposure (both p<0.001). Interestingly, 
both were detected in all subjects’ morning samples during GC withdrawal. 
However, both overnight urine cortisol and cortisone excretion were under the 
limit of detection during GC withdrawal, indicating very low GC exposure. 
There was no difference in systolic and diastolic blood pressure, body weight, 
serum sodium and potassium, and plasma glucose concentrations between the 
two interventions both at baseline and in the morning of the second day (when 
samples were collected for ‘omic analyses). 
 
Raw ‘Omic Data 
 
Firstly, a transcriptomics analysis of PBMC samples from the morning of the 
second day was performed. By comparing the two interventions, 289 
differentially expressed gene probe sets were identified (p<0.001, q<0.2) 
consisting of 234 unique known genes (data not shown). 
In the same comparison, nine of 252 analysed plasma miRNAs (from the 
morning of the second-day samples) were shown to be differentially expressed 
between the two interventions (Wilcoxon signed rank test p<0.05, data not 
shown). The nine miRNAs were then predicted to interact with 46 of the 234 
unique, differentially expressed genes from the transcriptomics analysis. 
The transcriptomics and miRNA analyses were then followed by serum 
metabolomics analysis (both midnight and morning) using both GC-MS and 
LC-MS. The analysis of metabolomic data using OPLS-DA showed clear 
clustering of metabolites by intervention and time points (Figure 7). 
Comparison of 164 metabolite fragments (82 derived from GC-MS and 82 
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from LC-MS) during the two interventions revealed a clear distinction between 
GC exposure and GC withdrawal. A paired t-test analysis identified 21 
metabolite fragments from GC-MS and 17 metabolite fragments from the 
LC-MS analysis that were significantly different (p<0.05) between the two 
interventions in the morning of the second-day samples (data not shown). 
 
Figure 7. Separation between experimental groups by OPLS-DA analysis for GC-MS data. 
Black squares depict midnight and morning samples from the GC withdrawal intervention and 
red squares depict midnight and morning samples from the intervention with physiological GC 
exposure. 
 
 
 
Interactome Network Model and Transcriptome Grid Diagram 
(Step 1 in Network Analysis) 
 
Biological pathways associated with differential gene expression observed 
between the two interventions in PBMCs collected in the morning of the 
second day were assessed. A range of classically GC responsive pathways 
were present, including GC receptor signalling and NF-κB signalling, along 
with a range of metabolism-linked pathways. These pathways together imply 
GC activity during the GC exposure intervention. 
We generated an interactome network model (with 2467 nodes) based on the 
234 unique, known genes with differential expression between the two 
interventions in the morning of the second day. Hierarchy of network modules 
based on network centrality score, a measurement of the proximity of the 
module to the centre of the network, is known to be related to functional 
importance [88-90]. We therefore defined the modules in the network model 
of differential gene expression associated with GC exposure in order to 
facilitate the integration of the other ‘omic datasets (miRNAs and metabolites). 
OPLS-DA o  Ca e/Con rol
Q2 = 0.66
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The differential gene expression within the central core (ten genes/proteins) of 
each of the top 25 network modules were visualised as a transcriptome grid 
diagram (in the middle of Figure 8) and was used as the basis for further 
analysis. The central genes of each network module were all shown to have 
relatively increased connectivity compared with the whole human interactome, 
and these observations suggest functional relevance and confirm network 
robustness. 
A range of genes in the interactome network model associated with GC action 
were shown to have evidence of NR3C1 binding to associated regulatory DNA 
elements (FKBP5, ZBTB16, IGF1R, PER1, TSC22D3, and NCOR2). These 
data were derived from the ENCODE database using a range of cell lines in 
response to a dexamethasone dose-response. 
 
Integration of miRomic and Metabolomic Data  
(Steps 2 and 3 in Network Analysis) 
 
In the differentially expressed genes were then mapped, six of the nine genes 
differentially expressed miRNAs (in the morning of the second-day samples). 
Of these six miRNAs, five mapped to the central core of the transcriptome 
network modules (Figure 8A). 
Independently from the first mapping, the 21 differentially regulated 
metabolite fragments in the morning of the second-day samples from the GC-
MS were mapped to the differentially expressed genes. This analysis 
demonstrated that some of these metabolites mapped to the central core of the 
transcriptome networks modules. It should be noted that this analysis showed 
the existence of two separate networks of metabolites (Figure 8B). 
 
In conclusion, findings from steps 1–3 include differentially regulated 
miRNAs and metabolites, which are associated with the differential gene 
expression and GC exposure. 
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Figure 8. MiRomic data and metabolomic data mapped independently to the interactome 
network model of differential gene expression (visualised by the its grid diagram) between the 
two interventions in morning samples. (A) Each miRNA is mapped to the position of the gene in 
the transcriptomic network model that it regulates. (B) The analysis demonstrated two separate 
network models (encircled in violet or orange colour) generated by combining transcriptomic 
and metabolomic data. 
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5 DISCUSSION 
Higher Risk of AD among Patients with T1DM 
 
Our incidence study estimated the incidence of AD among patients with T1DM 
in Sweden at 193 per million patient-years. Patients who already had T1DM 
showed a more than 10-fold higher risk of developing AD, which appeared at 
a younger age than in patients without T1DM. Finally, there seemed to be a 
male predominance in patients with T1DM that developed AD, which is in line 
with the male predominance of T1DM [59] and in contrast to the female 
predominance of AD in the general population [35,40-42]. 
These findings suggest that healthcare professionals who follow patients with 
T1DM should be aware for the possibility of the development of concomitant 
AD as this is much more common in this patient group. In contrast to AD in 
the general population where there is a female predominance and age at 
diagnosis peaks at 30–50 years of age, AD is more common in men and at 
younger age in patients with T1DM. 
 
Early Indicators of AD in Patients with T1DM 
 
To our knowledge, this is the first time that prodromal or early signs of AD 
have been systematically studied in patients with T1DM. We found that the 
following were more frequent among patients with T1DM who subsequently 
developed AD: 
- Treatment for thyroid diseases, 
- Severe infections requiring hospital admission, 
- Multiple diabetic complications and retinopathy in particular, 
- Rescue therapy for hypoglycaemia. 
In our study population, among patients with T1DM who developed AD, up to 
33% had treatment with thyroid and/or antithyroid drugs before and after the 
diagnosis of AD (4-fold higher in cases after AD diagnosis than in controls 
with T1DM). This is in line with a previous Swedish study reporting that 38% 
of patients with AD also had T1DM and autoimmune thyroid disease [43]. 
Already, at more than 2 years before our study patients were diagnosed with 
AD, they had a higher frequency of treatment for thyroid disease versus 
controls with T1DM alone. Our study therefore suggests that there should be 
an increased alertness for the possibility of developing AD (APS2) in patients 
with concurrent T1DM and autoimmune thyroid disease. 
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The appearance of severe infections requiring hospital admission in patients 
with T1DM may also alert the physician for the possibility of AD development. 
In our study population there was a significant difference in the frequency of 
such infections prior to AD diagnosis compared with control subjects (17% vs 
2%) and a similar trend was observed many years before the AD diagnosis 
(data not presented). Previous studies in patients with AD have shown a higher 
frequency of infections, including those requiring hospital admissions or a 
higher frequency of treatment with systemic antibiotics [43,91,92]. There are 
two possible explanations for this observation: either this is an effect of the 
increased vulnerability to infections in patients with AD as suggested in two 
previous studies [93,94] or that patients with concomitant T1DM have a lower 
threshold of being admitted to hospital because of dysregulated glycaemic 
control (or risk for that) during an infection. The latter explanation is less likely 
due to the case-control design of our study. 
Before the diagnosis of AD, patients with T1DM who developed AD had a 6-
fold higher frequency of diabetic retinopathy compared with matched control 
subjects. This finding might be related to the underlying systemic 
proinflammation or inflammation in patients with AD [95], as there is 
increasing evidence that diabetic retinopathy has an inflammatory background 
[96]. It is also shown that longer diabetes duration and poorer glycaemic and 
blood pressure control are strongly associated with diabetic retinopathy [97], 
but there was no difference in these parameters between cases and control 
subjects in the current study, strongly indicating that the development of AD 
per se is responsible for this increase. 
Glucagon is a therapy for acute hypoglycaemia and its prescription may, in 
some individuals, denote higher risk (or actually higher incidence) of 
hypoglycaemia. In our study, close to their AD diagnosis, patients with T1DM 
were prescribed glucagon at a rate 3-times higher than their matched controls 
with T1DM, suggesting higher risk (or incidence) of severe hypoglycaemia. 
These findings suggest that healthcare professionals who follow patients with 
T1DM should be alerted when such potential early clinical indicators arise and 
evaluate their patients for the risk of concomitant AD development. How this 
is best done in patients with T1DM is unclear. Morning serum cortisol and 
ACTH, and short synthetic ACTH stimulation test are generally the 
assessments of choice for the diagnosis of AD. Whether their specificity and 
sensitivity are as high in patients with T1DM has not been studied. 
 
Increased Mortality 
 
Our nationwide mortality study in patients with T1DM and AD showed a 4-
fold increased risk of overall mortality versus matched controls with T1DM. 
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This risk is on the top of the already increased mortality in Swedish patients 
with T1DM [63]. The most common main cause of death in patients with 
T1DM and AD was death related to diabetic complications, whereas the 
national Swedish study in patients with AD has shown cardiovascular causes 
as the most common cause of death [21], and another national Swedish study 
in patients with T1DM has shown both cardiovascular and diabetes-related 
causes as the most common causes of death [63]. In our study, infections and 
unknown causes of death were more common in patients with T1DM and AD 
than in those with T1DM alone. 
The increased rate of death from diabetes-related complications and infections 
might be due to their higher proportion already before the diagnosis of AD. In 
both our early indicators and mortality studies, where we followed up patients 
with T1DM who developed or did not develop AD (thus with different study 
periods and in partially overlapping populations), we observed a higher 
frequency of diabetic complications and infections requiring hospital 
admission before the diagnosis of AD versus matched controls with T1DM. 
The explanation for this is unclear, but it may be related to the fact that 
management of T1DM may be more difficult if the intrinsic regulation of 
cortisol secretion is impaired, which is likely to occur well in advance of the 
actual diagnosis of AD. Adrenal medulla function may also be impaired in 
patients with AD [98] and this may be deleterious in patients with T1DM when 
they are dependent on a catecholamine rescue mechanism during 
hypoglycaemia. 
At inclusion in the mortality study, the degree of cardiovascular comorbidities, 
cancer and glycaemic control did not differ markedly between cases and 
matched control subjects with T1DM, suggesting an impact of AD on excess 
mortality. A possible explanation for this deleterious effect of AD on mortality 
rate might be the counter-balancing metabolic effects of insulin and cortisol, 
the main treatments for T1DM and AD, respectively. 
Premature death due to cancer was more common among control subjects with 
T1DM versus those with T1DM and AD, suggesting that AD or its treatment 
with GCs may modify the increased risk of cancer death among patients with 
T1DM. A previous national Swedish study has shown increased cancer risk in 
patients with T1DM compared with the general population [99]. 
Hyperglycaemia, insulin resistance, hyperinsulinaemia and the effects of 
diabetes treatment have all been suggested as possible mechanisms for the 
increased cancer risk in type 2 diabetes [100]. Little is known about the effect 
of AD and its treatment on these parameters in patients having both T1DM and 
AD. 
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Risk of Adrenal Crisis 
 
There were some interesting findings in our epidemiological studies 
concerning the risk of adrenal crisis in patients with the combination of T1DM 
and AD. Previous studies have shown an increased risk of potentially life-
threatening adrenal crises among patients with both T1DM and AD versus 
those with AD alone or the general population [56,71,72]. Our mortality study 
supports these previous observations not only by identifying patients with 
adrenal crisis as the main cause of death but also by showing higher mortality 
from infections and unknown causes. These deaths may be explained by 
untreated or inadequately treated adrenal crises, severe hypoglycaemia or their 
combination. 
As adrenal crisis can be prevented by an adequate rescue regimen, our studies 
indicate the high risk of premature death from stress-related events 
when patients with both T1DM and AD are not treated properly. Because of 
the complex metabolic interplay between insulin and cortisol in patients with 
T1DM and AD, targeted information and education are needed to manage both 
diagnoses during an infection or other stressful events. 
 
Routine Screening of Patients with T1DM for AD 
 
The risk of associated autoimmune diseases (most commonly Hashimoto’s 
thyroiditis, coeliac disease, Graves’ disease, rheumatoid arthritis and vitiligo) 
is well defined in patients with T1DM [66]. The latest recommendations 
(2018) from American Diabetes Association concerning assessment of 
comorbidities suggest the routine evaluation of TSH for thyroid-associated 
diseases in patients with T1DM but not for AD [77]. The recommendation to 
screen for thyroid diseases but not AD in T1DM patients may be related to the 
rarity of the combination of T1DM and AD, and the fact that TSH monitoring 
is less expensive, less laborious and easier to interpret. There are currently no 
guidelines for routine screening for AD among patients with T1DM (with or 
without autoimmune thyroid disease) [73-76]. 
In the incidence study, we demonstrated that AD is 10 times more common in 
patients with T1DM and, in the mortality study, that AD markedly increases 
the overall risk of death in patients with T1DM, which both advocate for AD 
screening. Potential laboratory assessments for that would be serum morning 
cortisol and ACTH, plasma renin or 21-hydroxylase antibodies as reported in 
previous studies [39,73,101,102]. Nevertheless, a circulating biomarker (in a 
similar manner to HbA1c for the assessment of suspected diabetes) could be a 
complementary, or possibly even a first-line, laboratory measurement in the 
future for AD screening. 
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Discovery of Novel Putative Biomarkers of GC Action 
 
In our experimental study, we succeeded in generating two completely 
different states of GC exposure (near-physiological vs nearly undetectable) in 
subjects with AD, in whom we studied the short-time actions of GCs with the 
help of multiple ‘omic methods. The novelty of the study is that its results may 
improve the understanding of mechanistic pathways by which GCs act and 
identifying potential biomarkers from gene expression, metabolome and 
miRNAs derived from a step-wise integration of different ‘omic data into a 
network. 
The concentrations of cortisone and cortisol in serum and urine from the 
interventions both at baseline and in the morning of the second day as well as 
the absence of major confounders in the form of secondary events related to 
the GC withdrawal state indicate the success of the model. Moreover, the 
similar vital parameters, and glucose and electrolyte levels reduce the 
possibility of increased adrenergic drive related to the GC withdrawal state. 
The detectable levels of serum cortisol throughout GC withdrawal may be 
explained by residual adrenal steroid secretion in some patients [103] or 
possible conversion of cortisone to cortisol in liver and adipose tissue [104]. 
Some of the transcriptomic data were in line with previous findings, which 
supports the validity of the study model. Comparison between the central genes 
of each network module in the transcriptome network model with those 
involved in circadian clock rhythms [105], steroidogenesis [106], GC 
responsiveness (mainly in malignancies) [107-110], and a recent published list 
of genes with elevated expression in the adrenal cortex [111] showed that many 
of these known genes are present in our network, such as PER1, CRY1, CRY2, 
and GAB1. In the transcriptomic network modules, TSC22D3, which encodes 
the anti-inflammatory GC-induced leucine zipper protein (GILZ), occupied 
central positions. Expression of this gene appears to play a key role in the anti-
inflammatory and immunosuppressive effects of GCs. 
Some of our findings in the metabolome analysis were also in line with a 
recently published metabolomic study in patients with congenital adrenal 
hyperplasia on long-term GC treatment [112]. In our study, metabolites such 
as palmitic acid, palmitoleic acid, docosahexaenoic acid, tryptophan and 
octanoylcarnitine revealed a clear distinction between GC exposure and GC 
withdrawal (data not presented). In contrast to the gene expression and 
metabolome data, all the miRNA findings comparing short-time GC exposure 
to withdrawal were novel. 
In conclusion, the results obtained from this clinical model showed a coherence 
and were in alignment with what is known about GC response, indicating 
relevance in the clinical model. 
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6 CONCLUSION 
The main findings of this thesis are summarised in Figure 9. 
 
Figure 9. Main thesis findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis has demonstrated a higher risk of AD among patients with T1DM 
and higher mortality in patients with concurrent T1DM and AD, indicating 
the need for an improved strategy in the management of these patients. 
Patients with T1DM face an approximately 10.8-times increased risk of 
developing AD compared with the general population; furthermore, they 
develop AD approximately 6.3 years (mean value) earlier than those not 
having T1DM. Signs, such as medical treatment for thyroid disease, infections 
requiring hospitalization, prescription of glucagon and diabetic retinopathy, in 
patients with T1DM may raise the suspicion of undiagnosed concomitant AD. 
Also, when patients with T1DM are diagnosed with AD, they face an 
additional risk for premature death that is approximately 4.3-times higher than 
those with T1DM alone. 
Concerning improvement in the management of these patients with T1DM and 
AD, we need a biomarker to individualise GC replacement therapy in a similar 
manner to HbA1c being an excellent biomarker for insulin replacement therapy. 
The novel findings arising from our experimental study indicate such potential 
biomarkers for further validation. 
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7 FUTURE PERSPECTIVES 
Our data, which identified for the first time the impact of AD on outcome in 
patients with T1DM, support a low threshold for biochemical evaluation of AD 
development among patients with T1DM. In our opinion, this supports the re-
evaluation of a screening strategy for AD in patients with T1DM during their 
follow-up. At present, there is no national (in Sweden) or international 
consensus concerning this kind of screening. 
The combination of T1DM and AD is rare, and more uncommon than other 
combinations of autoimmune diseases in T1DM patients. Nevertheless, data 
on the deleterious effect of AD (when it is diagnosed) on mortality rate and the 
increased risk for adrenal crises versus patients with AD alone support the need 
for an improved management strategy of these patients. 
For patients already diagnosed with this combination, who struggle to balance 
the risks of hypoglycaemia and adrenal crisis, which both potentially lead to 
coma, targeted information and education are needed. A possible way of 
achieving this might be by patient education programmes similar to those 
that have been developed for patients with T1DM or AD. Another way, both 
for patients and healthcare providers, might be by distribution and completion 
of special “insulin-steroid cards” similar to those that have already been 
implemented for patients with AD alone. 
One possible next step in the understanding of the metabolic interplay between 
insulin and cortisol in these patients might be an interventional study with 
continuous measurement of glucose and GC levels in patients with different 
combinations of various insulin and GC preparations. Such a study might 
provide more insights into the mechanisms behind this metabolic interplay and 
might answer the question of which is the best combination of replacement 
therapy with different insulin and GC preparations to mitigate the risk of 
premature death. 
Moreover, in order to come closer to a valuable and clinically useful 
biomarker(s) of GC action, we have to validate and confirm our findings (gene 
expression, miRNAs and metabolites) in other populations (e.g. in patients 
with GC over-production/over-substitution and healthy individuals) or 
different states of GC substitution in patients with AD (with or without 
T1DM). 
Such a circulating biomarker (in a similar manner to HbA1c in diabetes 
assessment) might become a complementary, or even first-line, laboratory 
measurement for routine screening for AD in patients with T1DM in the future. 
Moreover, it might also useful for individualising GC treatment in patients 
with AD, exactly as HbA1c does in T1DM. 
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APPENDIX 
Supplementary table: ICD-9 and ICD-10 codes of the diagnoses used in the 
studies 
 
Group of diagnoses Diagnosis ICD-9 code ICD-10 code 
Addison's disease Addison's disease 255.4 E27.1 
Addisonian crisis – E27.2 
Diabetes mellitus All types 250 – 
Type 1 – E10 
Type 2 – E11 
Malnutrition-
related 
– E12 
Other specified – E13 
Unspecified – E14 
Cushing´s syndrome (drug-induced Cushing 
syndrome not included) 
255.0 E24.0–E24.1, E24.3–
E24.9 
Hypofunction and other 
disorders of the 
pituitary gland 
Disorders of the 
pituitary gland and 
its hypothalamic 
control 
253 – 
Pituitary neoplasia 227.3 – 
Hypofunction and 
other disorders of 
the pituitary gland 
– E23 
Malignant neoplasm of the adrenal gland  194.0 C74.9 
Anomalies of the adrenal gland (congenital)  759.1 – 
Post-procedural adrenocortical (-medullary) 
hypofunction 
– E89.6 
Cancer 140–208 C00–C97 
Acute myocardial infarction 410 I21 
Coronary heart disease (acute myocardial 
infarction included) 
410–414 I20–I25 
Atrial fibrillation 
Cardiac dysrhythmias (atrial fibrillation 
included) 
427.3 
427 
I48 
I47, I48, I49 
Heart failure 428 I50 
Hypertension 401–405 I10–I15 
Thyroid diseases (all) 
Autoimmune thyroid diseases 
 
 
Celiac disease 
Rheumatoid arthritis 
 
Systemic lupus erythematosus 
240–246 
242.0, 242.9, 
244.9, 245.2, 
245.8, 245.9 
579.0 
714.0–714.2, 
714.8, 714.9 
710.0 
E00–E07 
E03.5, E03.9, E05.0, 
E05.5, E05.9, E06.3, 
E06.5 
K90.0 
M05, M06 
 
M32 
Stroke 
Haemorrhagic stoke 
Cerebral Infarction 
431, 432, 434 
431, 432 
434 
I61–I64 
I61, I62 
I63 
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Diabetes mellitus-
related complications 
Ophthalmic  250.5 E10.3, E11.3, E12.3, 
E13.3, E14.3 
Neurological  250.6, 357.2 E10.4, E11.4, E12.4, 
E13.4, E14.4, G63.2 
Peripheral 
circulatory  
250.7 E10.5, E11.5, E12.5, 
E13.5, E14.5, I79.2 
Other specified  250.8 E10.6, E11.6, E12.6, 
E13.6, E14.6 
Multiple  – E10.7, E11.7, E12.7, 
E13.7, E14.7 
Unspecified 
 
Nephropathy 
 
DM with foot 
ulcer 
Amputation of 
limb 
250.9 
 
250.4 
 
– 
 
E878.5 
E10.8, E11.8, E12.8, 
E13.8, E14.8 
E10.2, E11.2, E12.2, 
E13.2, E14.2 
E10.6D, E11.6D 
 
Y83.5 
Infections requiring 
admission to hospital 
(inclusive erysipelas) 
Diabetic hypoglycaemia 
Infections 001–041, 480–
487, 599 
A00–A49, J09–J18, 
J20–J22, N39.0 
Erysipelas 035 
250.8 
A46 
E.16.0, E16.2, 
E10.6A, E11.6A 
Chronic kidney disease 585, 586 N18, N19 
ICD-9: International Classification of Diseases, Ninth Revision; ICD-10: International 
Classification of Diseases, Tenth Revision 
 
